Skip to main content
Log in

The efficacy of salvage autologous stem cell transplant among patients with multiple myeloma who received maintenance therapy post initial transplant

  • Correspondence
  • Published:
Bone Marrow Transplantation Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, et al. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016;3:e340–51. https://doi.org/10.1016/S2352-3026(16)30049-7.

    Article  PubMed  Google Scholar 

  2. Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:874–85. https://doi.org/10.1016/S1470-2045(14)70245-1.

    Article  CAS  PubMed  Google Scholar 

  3. Atanackovic D, Schilling G. Second autologous transplant as salvage therapy in multiple myeloma. Br J Haematol. 2013;163:565–72. https://doi.org/10.1111/bjh.12579.

    Article  PubMed  Google Scholar 

  4. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20. https://doi.org/10.1200/JCO.2005.04.242.

    Article  PubMed  Google Scholar 

  5. Vincent Rajkumar S. Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89:999–1009. https://doi.org/10.1002/ajh.23810.

    Article  CAS  PubMed  Google Scholar 

  6. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73. https://doi.org/10.1038/sj.leu.2404284.

    Article  CAS  PubMed  Google Scholar 

  7. Singh Abbi KK, Zheng J, Devlin SM, Giralt S, Landau H. Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma. Biol Blood Marrow Transplant. 2015;21:468–72. https://doi.org/10.1016/j.bbmt.2014.11.677.

    Article  PubMed  Google Scholar 

  8. Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G, et al. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer. 2012;118:3549–55. https://doi.org/10.1002/cncr.26662.

    Article  PubMed  Google Scholar 

  9. Grovdal M, Nahi H, Gahrton G, Liwing J, Waage A, Abildgaard N, et al. Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT. Bone Marrow Transplant. 2015;50:808–12. https://doi.org/10.1038/bmt.2015.39.

    Article  CAS  PubMed  Google Scholar 

  10. Jimenez-Zepeda VH, Mikhael J, Winter A, Franke N, Masih-Khan E, Trudel S, et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant. 2012;18:773–9. https://doi.org/10.1016/j.bbmt.2011.10.044.

    Article  PubMed  Google Scholar 

  11. Gonsalves WI, Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Second auto-SCT for treatment of relapsed multiple myeloma. Bone Marrow Transplant. 2013;48:568–73. https://doi.org/10.1038/bmt.2012.183.

    Article  CAS  PubMed  Google Scholar 

  12. Sellner L, Heiss C, Benner A, Raab MS, Hillengass J, Hose D, et al. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients. Cancer. 2013;119:2438–46. https://doi.org/10.1002/cncr.28104.

    Article  CAS  PubMed  Google Scholar 

  13. Gimsing P, Hjertner O, Abildgaard N, Andersen NF, Dahl TG, Gregersen H, et al. Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial. Bone Marrow Transplant. 2015;50:1306–11. https://doi.org/10.1038/bmt.2015.125.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, et al. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant. 2015;21:2039–51. https://doi.org/10.1016/j.bbmt.2015.09.016.

    Article  PubMed  PubMed Central  Google Scholar 

  15. McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ravi Vij.

Ethics declarations

Conflict of interest

RV: Bristol-Myers Squibb: Consultancy and Research Support; Takeda: Consultancy and Research Support; Amgen: Consultancy and Research Support; Celgene: Consultancy and Research Support; Janssen: Consultancy; Novartis: Consultancy; Jazz: Consultancy; Karyopharma: Consultancy. The remaining authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Manjappa, S., Fiala, M.A., King, J. et al. The efficacy of salvage autologous stem cell transplant among patients with multiple myeloma who received maintenance therapy post initial transplant. Bone Marrow Transplant 53, 1483–1486 (2018). https://doi.org/10.1038/s41409-018-0216-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0216-3

  • Springer Nature Limited

This article is cited by

Navigation